human recombinant interleukin-2 ( ril-2 ) was administered to normal and tumor-bearing bdf mice for 1 to 3 weeks , and the hematologic , clinical chemistry , gross and histopathologic findings were evaluated .
C0086418
human
C0021756
recombinant interleukin-2